// App-Quantinova.ai

32 : Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC).

Researchers

Presenter

  • John B. A. G. Haanen

Principal Investigators

  • Joanna C. Masters

  • Bo Huang

  • Toni K. Choueiri

  • Robert J. Motzer

  • Akash Khandelwal

  • Haiqing (Isaac) Dai

  • Alessandra di Pietro

  • Satjit Brar

  • Brian I. Rini

  • Laurence Albiges

  • James M. G. Larkin

Medical Centers

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Pfizer Oncology, La Jolla, CA

  • Pfizer, Groton, CT

  • Dana-Farber Cancer Institute/Brigham and Women’s Hospital and Harvard University School of Medicine, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Merck KGaA, Darmstadt, Germany

  • EMD Serono Inc. (A business of Merck KGaA, Darmstadt, Germany), Rockland, MA

  • Pfizer Inc, Milan, Italy

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Institut Gustave-Roussy, Villejuif, France

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • Netherlands

  • United States

  • Germany

  • Italy

  • France

  • United Kingdom

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Inlyta

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02493751

  • NCT02684006

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved